139 related articles for article (PubMed ID: 34929056)
1. Impact of bone marrow involvement on early positron emission tomography response and progression-free survival in the HD18 trial for patients with advanced-stage Hodgkin lymphoma.
Kreissl S; Voltin CA; Kaul H; Bühnen I; Mettler J; Pabst T; Eichenauer DA; Fuchs M; Diehl V; Dietlein M; Engert A; Borchmann P; Kobe C
Br J Haematol; 2022 Apr; 197(1):e5-e8. PubMed ID: 34929056
[No Abstract] [Full Text] [Related]
2. Change of initial staging at early remission evaluation with FDG-PET/CT in Hodgkin lymphoma: a report of two cases.
Molin D; Hagberg H; Suurküla M; Aström G
Acta Oncol; 2010 May; 49(4):526-8. PubMed ID: 20397779
[No Abstract] [Full Text] [Related]
3. Value of bone marrow biopsy in Hodgkin lymphoma patients staged by FDG PET: results from the German Hodgkin Study Group trials HD16, HD17, and HD18.
Voltin CA; Goergen H; Baues C; Fuchs M; Mettler J; Kreissl S; Oertl J; Klaeser B; Moccia A; Drzezga A; Engert A; Borchmann P; Dietlein M; Kobe C
Ann Oncol; 2018 Sep; 29(9):1926-1931. PubMed ID: 30010775
[TBL] [Abstract][Full Text] [Related]
4. [18F]fluorodeoxyglucose positron emission tomography in the management of lymphomas.
Kostakoglu L
Clin Lymphoma Myeloma; 2008 Oct; 8(5):273-6. PubMed ID: 18854280
[No Abstract] [Full Text] [Related]
5. PET-guided eBEACOPP treatment of advanced-stage Hodgkin lymphoma (HD18): follow-up analysis of an international, open-label, randomised, phase 3 trial.
Kreissl S; Goergen H; Buehnen I; Kobe C; Moccia A; Greil R; Eichenauer DA; Zijlstra JM; Markova J; Meissner J; Feuring-Buske M; Soekler M; Beck HJ; Willenbacher W; Ludwig WD; Pabst T; Topp MS; Hitz F; Bentz M; Keller UB; Kühnhardt D; Ostermann H; Hertenstein B; Aulitzky W; Maschmeyer G; Vieler T; Eich H; Baues C; Stein H; Fuchs M; Diehl V; Dietlein M; Engert A; Borchmann P;
Lancet Haematol; 2021 Jun; 8(6):e398-e409. PubMed ID: 34048679
[TBL] [Abstract][Full Text] [Related]
6. Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin's lymphoma treated with BEACOPP
Borchmann P; Haverkamp H; Lohri A; Mey U; Kreissl S; Greil R; Markova J; Feuring-Buske M; Meissner J; Dührsen U; Ostermann H; Keller U; Maschmeyer G; Kuhnert G; Dietlein M; Kobe C; Eich H; Baues C; Stein H; Fuchs M; Diehl V; Engert A
Lancet Oncol; 2017 Apr; 18(4):454-463. PubMed ID: 28236583
[TBL] [Abstract][Full Text] [Related]
7. Assessment of tumor size reduction improves outcome prediction of positron emission tomography/computed tomography after chemotherapy in advanced-stage Hodgkin lymphoma.
Kobe C; Kuhnert G; Kahraman D; Haverkamp H; Eich HT; Franke M; Persigehl T; Klutmann S; Amthauer H; Bockisch A; Kluge R; Wolf HH; Maintz D; Fuchs M; Borchmann P; Diehl V; Drzezga A; Engert A; Dietlein M
J Clin Oncol; 2014 Jun; 32(17):1776-81. PubMed ID: 24799482
[TBL] [Abstract][Full Text] [Related]
8. US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging: Southwest Oncology Group S0816.
Press OW; Li H; Schöder H; Straus DJ; Moskowitz CH; LeBlanc M; Rimsza LM; Bartlett NL; Evens AM; Mittra ES; LaCasce AS; Sweetenham JW; Barr PM; Fanale MA; Knopp MV; Noy A; Hsi ED; Cook JR; Lechowicz MJ; Gascoyne RD; Leonard JP; Kahl BS; Cheson BD; Fisher RI; Friedberg JW
J Clin Oncol; 2016 Jun; 34(17):2020-7. PubMed ID: 27069074
[TBL] [Abstract][Full Text] [Related]
9. Expert opinions on positron emission tomography and computed tomography imaging in lymphoma.
Delbeke D; Stroobants S; de Kerviler E; Gisselbrecht C; Meignan M; Conti PS
Oncologist; 2009; 14 Suppl 2():30-40. PubMed ID: 19819922
[TBL] [Abstract][Full Text] [Related]
10. Interpretation and validation of interim positron emission tomography in Hodgkin lymphoma.
Kobe C; Dietlein M; Fuchs M
Leuk Lymphoma; 2010 Mar; 51(3):552-3. PubMed ID: 20141443
[No Abstract] [Full Text] [Related]
11.
Hassan A; Siddique M; Bashir H; Riaz S; Wali R; Mahreen A; Nawaz MK
Eur J Nucl Med Mol Imaging; 2017 Jul; 44(7):1198-1206. PubMed ID: 28229191
[TBL] [Abstract][Full Text] [Related]
12. Can [18F]fluorodeoxyglucose positron emission tomography imaging complement biopsy results from the iliac crest for the detection of bone marrow involvement in patients with malignant lymphoma?
Fuster D; Chiang S; Andreadis C; Guan L; Zhuang H; Schuster S; Alavi A
Nucl Med Commun; 2006 Jan; 27(1):11-5. PubMed ID: 16340718
[TBL] [Abstract][Full Text] [Related]
13. Can fluorodeoxyglucose positron emission tomography/computed tomography avoid negative iliac crest biopsies in evaluation of marrow involvement by lymphoma at time of initial staging?
Mittal BR; Manohar K; Malhotra P; Das R; Kashyap R; Bhattacharya A; Varma N; Varma S
Leuk Lymphoma; 2011 Nov; 52(11):2111-6. PubMed ID: 21745169
[TBL] [Abstract][Full Text] [Related]
14. [Picture in Clinical Hematology No. 106].
Rinsho Ketsueki; 2017; 58(8):903. PubMed ID: 28883271
[No Abstract] [Full Text] [Related]
15. Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma.
Kobe C; Dietlein M; Franklin J; Markova J; Lohri A; Amthauer H; Klutmann S; Knapp WH; Zijlstra JM; Bockisch A; Weckesser M; Lorenz R; Schreckenberger M; Bares R; Eich HT; Mueller RP; Fuchs M; Borchmann P; Schicha H; Diehl V; Engert A
Blood; 2008 Nov; 112(10):3989-94. PubMed ID: 18757777
[TBL] [Abstract][Full Text] [Related]
16. 2-deoxy-2[F-18] fluoro-D-glucose positron emission tomography Deauville scale and core-needle biopsy to determine successful management after six doxorubicin, bleomycin, vinblastine and dacarbazine cycles in advanced-stage Hodgkin lymphoma.
Picardi M; Fonti R; Della Pepa R; Giordano C; Pugliese N; Nicolai E; Salvatore M; Mainolfi C; Venetucci P; Rascato MG; Cappuccio I; Mascolo M; Vigliar E; Troncone G; Del Vecchio S; Pane F
Eur J Cancer; 2020 Jun; 132():85-97. PubMed ID: 32334339
[TBL] [Abstract][Full Text] [Related]
17. In vivo treatment sensitivity testing with positron emission tomography/computed tomography after one cycle of chemotherapy for Hodgkin lymphoma.
Hutchings M; Kostakoglu L; Zaucha JM; Malkowski B; Biggi A; Danielewicz I; Loft A; Specht L; Lamonica D; Czuczman MS; Nanni C; Zinzani PL; Diehl L; Stern R; Coleman M
J Clin Oncol; 2014 Sep; 32(25):2705-11. PubMed ID: 25071108
[TBL] [Abstract][Full Text] [Related]
18. Focal skeletal FDG uptake indicates poor prognosis in cHL regardless of extent and first-line chemotherapy.
Pedersen MA; Gormsen LC; Kamper P; Wassberg C; Andersen MD; d'Amore AL; Barrington SF; Johnson P; Hamilton-Dutoit S; Amini RM; Enblad G; Molin D; d'Amore F
Br J Haematol; 2019 Aug; 186(3):431-439. PubMed ID: 31115045
[No Abstract] [Full Text] [Related]
19. Combination chemoradiotherapy in early Hodgkin lymphoma.
André MP
Hematol Oncol Clin North Am; 2014 Feb; 28(1):33-47. PubMed ID: 24287066
[TBL] [Abstract][Full Text] [Related]
20. Evidence of a graft-versus-Hodgkin lymphoma effect in the setting of extensive bone marrow involvement.
Anderlini P; Swanston N; Rashid A; Bueso-Ramos C; Macapinlac HA; Champlin RE
Biol Blood Marrow Transplant; 2008 Apr; 14(4):478-80. PubMed ID: 18342791
[No Abstract] [Full Text] [Related]
[Next] [New Search]